RETINALGENIX TECHNOLOGIES INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
RETINALGENIX TECHNOLOGIES INC. (RTGN) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $2.03 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2024-04-01
- RETINALGENIX TECHNOLOGIES INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-12-31 was $0.00.
- RETINALGENIX TECHNOLOGIES INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2022-09-30 was $2.03M.
- RETINALGENIX TECHNOLOGIES INC. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $2.03M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.03M derived: sum of 2 quarters · filed 2024-04-01 | $2.03M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $2.03M 10-Q · filed 2023-11-14 | $2.03M 10-Q · filed 2023-11-14 |